Intestinal ischemia-reperfusion (I/R) occurs in a wide variety of clinical settings, including hemorrhagic shock, acute mesenteric ischemia, and organ transplantation, 1 resulting in a high mortality rate. 2 Although various therapeutic methods exist, 1 including ischemic preconditioning, antioxidant therapy, anticomplement therapy, and antileukocyte therapy, no definite therapeutic strategy is available for intestinal I/R injury. We and others have shown that cell apoptosis is a significant contributor to intestinal I/R injury. 3, 4, 5 However, the underlying mechanisms are not completely understood.
The protein kinase C (PKC) family consists of 12 structurally related members that function as serine/threonine kinases. 6 PKC has essential roles in various fundamental cellular processes, including survival, proliferation, differentiation, and apoptosis. 7 PKCζ is one member of the atypical protein kinase C (aPKC) subfamily, 8 which is expressed in intestinal stem cells and colon cancer cells. 9, 10, 11 PKCζ knockdown or dominant-negative PKCζ expression increases cell apoptosis, 10, 11, 12 suggesting that PKCζ is an anti-apoptotic protein. Although one study found that PKCζ was involved in MAPK activation in H9c2 cells (an embryonic rat heart-derived cell line) subjected to reoxygenation after ischemic hypoxia, 13 the role of PKCζ in intestinal I/R injury is unknown.
Tumor necrosis factor (TNF) receptor-associated factor (TRAF) proteins are adaptor molecules that associate the TNF receptor family with a variety of signaling pathways related to cell survival and cellular responses to stress. 14 Previous studies revealed that TRAF2, which is a representative member of the TRAF family, promoted cell survival in response to TNF-α stimulation. 15 In addition, TRAF2 depletion augmented hepatocyte apoptosis via Fas/CD95, 16 implying that TRAF2 has a role in suppressing apoptosis in the liver. Research into myocardial I/R injury revealed that cardiac-restricted expression of dominant-negative TRAF2 significantly increased injury, 17 indicating a role for TRAF2 as a cytoprotective factor in myocardial I/R. Furthermore, TRAF2 KO mice exhibited increased proinflammatory cytokine expression and colonic epithelial cell apoptosis, leading to the spontaneous development of inflammatory bowel disease (IBD). 18 However, research has indicated that TRAF2 KO mouse embryonic fibroblasts (MEFs) are resistant to cell death induced by reactive oxygen species (ROS), 19 suggesting that TRAF2 can promote ROS-induced cell death. Thus, TRAF2 has distinct roles in different cell systems and settings. Therefore, we speculated that TRAF2 may also be involved in intestinal I/R injury and were interested in exploring the specific effect of TRAF2 on intestinal I/R injury.
PKCζ phosphorylates TRAF2 at Ser 55 in response to TNF-α stimulation, which allows the phosphorylated TRAF2 to suppress apoptosis, leading to inhibition of TNF-α-induced cell death in MEFs. 20 Consequently, in this study, we sought to investigate the role of the PKCζ/TRAF2 signaling pathway in intestinal I/R injury.
Results
Intestinal I/R induces the membrane translocation and phosphorylation of PKCζ. We had previously confirmed the intestinal I/R-mediated membrane translocation and phosphorylation of PKCβ 2 , but not PKCβ 1 , PKCδ, or PKCε. 21 To explore the protein expression of aPKC subfamily members (PKCζ and PKCλ) in intestinal I/R injury, we evaluated related membrane proteins in intestinal tissues subjected to 45 min of ischemia, followed by 60, 120 or 240 min of reperfusion. The selective membrane translocation of PKCζ, but not of PKCλ (the other member of the aPKC subfamily), was tested in the membrane fraction after different reperfusion times (Figure 1a) . The results indicated that PKCζ, but not PKCβ 2 , was particularly activated by intestinal I/R.
We examined PKCζ phosphorylation after a 120-min reperfusion and found a significant increase at the Thr 410 residue, which resulted in a marked increase in the phosphorylated PKCζ/total PKCζ ratio ( Figure 1b) . Overall, these findings suggested that PKCζ translocates to the plasma membrane and is phosphorylated in response to intestinal I/R.
PKCζ attenuates the gut injury induced by intestinal I/R. To assess the function of PKCζ in the intestinal I/R model, we used the PKCζ activator phosphatidylcholine (PC) and the PKCζ inhibitor aurothiomalate (ATM). 22, 23 First, we examined the effect of exposure of PKCζ to PC or ATM. The data suggested that PC increased the expression and phosphorylation of PKCζ, whereas ATM had the opposite effect (Figures 2a and b ). Next, we tested the effects of PC and ATM on histological changes in intestinal tissue in response to intestinal I/R injury. Compared with the sham group, the intestinal I/R group showed severe hyperemia and a loss of intestinal villi (Figure 2c ). PC clearly reduced the intestinal injury and histopathology score, however, the group treated with ATM under intestinal I/R conditions displayed visibly worsened injury and an increased histopathology score (Figures 2c and d) . Collectively, these findings suggested that an increase in PKCζ activation attenuated the gut injury induced by intestinal I/R.
PKCζ suppresses intestinal I/R injury by inhibiting gut apoptosis. To define the mechanism underlying the protective effect of PKCζ in intestinal I/R injury, we conducted a terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) assay to evaluate if PKCζ affects apoptosis. Compared with the sham group, the intestinal I/R group presented a significant increase in apoptotic cells. Conversely, pretreatment with PC resulted in a distinct reduction in the number of apoptotic cells (Figure 3a) . However, the number of apoptotic intestinal cells was increased in the group treated with ATM under intestinal I/R conditions (Figure 3a) . Moreover, PC apparently suppressed the expression of the pro-apoptotic protein cleaved caspase-3 and increased the expression of the anti-apoptotic protein Bcl-2 ( Figure 3b) . Overall, the data suggested that an increase in PKCζ activation could alleviate the apoptosis induced by intestinal I/R. PKCζ colocalizes with TRAF2 after H/R and TRAF2 is phosphorylated in response to intestinal I/R. To explore the mechanism by which PKCζ phosphorylation alleviated the apoptosis induced by intestinal I/R, human Caco-2 cells were treated with hypoxia/reoxygenation (H/R) to mimic the intestinal I/R model. We found that PKCζ and TRAF2 were recruited to the plasma membrane and combined with each other after H/R treatment (Figure 4a ). Western blotting further verified the membrane translocation of PKCζ and TRAF2 in Caco-2 cells under H/R conditions ( Figure 4b ). Next, we conducted a co-immunoprecipitation experiment to examine the association between PKCζ and TRAF2. Membranes isolated from Caco-2 cells in the absence of H/R (control) showed colocalization of PKCζ and TRAF2 in the same immunocomplex, whereas H/R increased the appearance of TRAF2 in the PKCζ immunoprecipitates (Figure 4c ).
We also examined TRAF2 phosphorylation in response to intestinal I/R. The results suggested that TRAF2 was phosphorylated at both Ser 55 and Ser 11 , but the total TRAF2 expression level did not change (Figure 4d ). Therefore, our data showed that TRAF2 was recruited to the plasma membrane and combined with PKCζ in Caco-2 cells under H/R conditions, and TRAF2 was activated through phosphorylation at both Ser 55 and Ser 11 in intestinal I/R.
TRAF2 is phosphorylated by PKCζ at Ser 55 but not at Ser 11 in response to intestinal I/R or H/R. To determine whether both Ser 55 and Ser 11 of TRAF2 were phosphorylated by PKCζ, we performed in vivo and in vitro experiments. The results of the in vivo experiment showed that p-TRAF2-Ser55 expression was markedly increased by pretreatment with PC, whereas TRAF2 phosphorylation at Ser 55 was reduced in the groups treated with ATM ( Figure 5a ). However, no effect on p-TRAF2-Ser11 expression was observed regardless of pretreatment with PC or ATM (Figure 5a ).
To confirm that PKCζ was involved in TRAF2 activation at Ser 55 but not Ser 11 , we knocked down endogenous PKCζ in Caco-2 cells using a typical siRNA approach (Figures 5b and c). The siRNA-mediated knockdown of PKCζ significantly suppressed the expression of PKCζ and p-PKCζ in Caco-2 cells (Figure 5b) . Notably, knockdown of PKCζ also reduced TRAF2 phosphorylation at Ser 55 but had no effect on Figure S1 ). Caco-2 cells were transfected with TRAF2-WT, TRAF2-S55A, or TRAF2-S55D and then subjected to H/R or left untreated. Based on the cell morphology and cell viability assay, pretreatment with TRAF2-S55D reduced cell death (Figures 6a and b) . To clarify the underlying mechanism, we (Figure 6c) . Moreover, the western blotting results confirmed that Caco-2 cells treated with TRAF2-S55D exhibited reduced cleaved caspase-3 expression and increased Bcl-2 expression (Figure 6d ). In summary, the data suggested that TRAF2 Ser 55 phosphorylation increased cell survival by inhibiting cell apoptosis in Caco-2 cells under H/R conditions.
TRAF2 Ser
55 phosphorylation promotes NF-κB activation but suppresses c-Jun activation under H/R conditions. To assess the underlying anti-apoptotic mechanism of TRAF2 Ser 55 phosphorylation in Caco-2 cells under H/R conditions, Caco-2 cells were transfected with TRAF2-WT, TRAF2-S55A, or TRAF2-S55D and then subjected to H/R or left untreated. Luciferase reporter gene assays in Caco-2 cells revealed that TRAF2-S55D transfection increased NF-κB activity compared with TRAF2-S55A transfection (Figure 7a ). To further evaluate the effect of TRAF2 Ser 55 phosphorylation on NF-κB activation, we examined the expression of NF-κB-related target genes by real-time PCR in Caco-2 cells under untreated or H/R conditions. Consistent with the luciferase reporter gene assay result, Caco-2 cells transfected with TRAF2-S55D had obviously promoted expression of cIAP1 and IP-10 in response to H/R compared with cells transfected with TRAF2-S55A (Figures 7b and c) . In contrast, western blotting showed that TRAF2-S55D transfection reduced the phosphorylation of c-Jun compared with TRAF2-S55A transfection (Figure 7d ). Taken together, these data suggested that phosphorylation of TRAF2 at Ser 55 promoted NF-κB activation but suppressed c-Jun activation in Caco-2 cells under H/R conditions.
Discussion
Intestinal ischemia and subsequent reperfusion injuries give rise to oxidative stress and the release of inflammatory mediators, 24, 25 such as TNF-α and IL-6, 5,26 resulting in a high mortality rate that ranges from 70 to 80%. 27, 28 We previously verified that intestinal I/R induced the expression of ROS and TNF-α. 4, 21 Apoptosis has an essential role in intestinal I/R, although the molecular basis is complex. 29 The protective effects of PKCζ in myocardial I/R have been confirmed in in vivo experiments. 13 In addition, the protective role of TRAF2 in myocardial I/R has been verified in in vitro experiments. 
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Targeting TRAF2 regulates gut ischemia-reperfusion W Zhou et al However, the underlying mechanisms remain unclear. The results of the present study demonstrated that the PKCζ/ TRAF2 signaling pathway alleviates intestinal I/R injury by suppressing apoptosis.
Although PKCβ 1 , PKCδ, and PKCε protein expression was examined in intestinal tissues, only the level of PKCβ 2 expression increased in response to intestinal I/R. 21 Similarly, in this study, we found that PKCζ, but not PKCλ, was selectively enhanced in response to reperfusion for various times (Figure 1a ). According to research on the TC10 pathway, TC10 recruits PKCζ/λ to the plasma membrane after insulin stimulation. 30 However, one investigation of myocardial I/R injury suggested that PI3K activated PKCζ and then translocated to the nucleus from the cytoplasm. 13 In our study, PKCζ displayed membrane translocation in response to intestinal I/R (Figure 1a ). These data suggested that PKCζ presents distinct tissue-specific functions.
PKCζ is activated mainly through three different mechanisms: phosphorylation at Thr 410 , auto-phosphorylation at Thr 560 , and release of the pseudo-substrate sequence via a conformational change. 31 Recent research has indicated that lyso-PC, a product of the hydrolysis of PC, could effectively activate PKCζ in melanocytes, NK cells, and intestinal tissue. 23, 32, 33 Specifically, lyso-PC stimulates PKCζ activation in melanocytes or NK cells through the mechanism involving phosphorylation or auto-phosphorylation, respectively. 32, 33 In the results presented here, phosphorylation of PKCζ was increased after treatment of mice with PC (Figure 2b ). To further evaluate the effect of PKCζ on intestinal I/R injury, we treated mice with the PKCζ inhibitor ATM, which is currently in phase I clinical testing for non-small cell lung cancer (NSCLC). 34 The PB1 functional domain has a crucial role in regulating the activity of the aPKC subfamily members. 35, 36 in addition, the PB1 domain is intimately related to cell proliferation and cell survival. 37 ,38 ATM has an anti-tumor role in pancreatic cancer and NSCLC through the highly selective targeting of Cys-68 within the PB1 domain of PKCζ or Cys-69 within the PB1 domain of PKCι. 22, 39 Our results showed that ATM pretreatment could decrease the expression of PKCζ (Figure 2a ). These data indicated that PC and ATM were evidently effective in regulating the activity of PKCζ in the intestine.
The TRAF family consists of six members. TRAF2 is the most extensively studied member in terms of function and structure.
14 Moreover, TRAF2 activation and regulation are complex events. Phosphorylation of TRAF2 occurs at diverse residues, including Ser 55 , Ser 11 , and Thr
117
, which is mediated by PKCζ, the IKKε kinases, and PKCδ/ε, respectively. 20, 40, 41 In this study, we found that Ser 55 and Ser 11 of TRAF2 were both phosphorylated in the intestinal I/R model (Figure 4d) . Interestingly, through the activation or knockdown of PKCζ in vivo and in vitro, we verified that PKCζ phosphorylated TRAF2 at Ser 55 , but not at Ser 11 , in response to intestinal I/R or H/R ( Figure 5) . A previous study indicated that TNF-α stimulation induced PKCζ to directly phosphorylate TRAF2 at Ser 55 . 20 In parallel, our immunofluorescence and co-immunoprecipitation assays showed that H/R stimulation of Caco-2 cells induced PKCζ to combine with TRAF2 (Figures 4a and c) .
TRAF2 is involved in a variety of clinical diseases, including different types of cancer, 42, 43 IBD, 18 and multiple pathologically induced myocardial I/R injury. 17 However, the effect of TRAF2 on cell survival varies under diverse conditions. Some studies have suggested that TRAF2 reduces the cell death induced by TNF-α stimulation. 15, 20, 44 In contrast, one study claimed that TRAF2 significantly promoted ROSinduced cell death. 19 In this study, we showed that TRAF2 Ser 55 phosphorylation clearly attenuated cell death ( Figures  6a and b) , suggesting that TRAF2 played a protective role in Caco-2 cells under H/R conditions. The TUNEL assay and evaluation of cleaved caspase-3 and Bcl-2 expression ultimately demonstrated that the mechanism underlying the protective effects of TRAF2 involved the suppression of cell apoptosis (Figures 6c and d) . Therefore, we believe that TRAF2 can decrease cell death by inhibiting apoptosis in Caco-2 cells subjected to H/R. The mechanism underlying TRAF2-mediated suppression of apoptosis is complex. Some research has confirmed that TRAF2 functions in the regulation of the NF-κB and c-Jun signaling pathways. 15, 20 Moreover, NF-κB has a vital role in inhibiting apoptosis, 45 whereas c-Jun is crucial in the proapoptosis cascade. 46 The anti-apoptotic effect of NF-κB may be related to Bcl-2, a key target gene of NF-κB, 47, 48 and overexpression of Bcl-2 can rescue cells from I/R-and H/Rinduced apoptosis. 49, 50 Noteworthily, a recent study about the sexual differentiation of the anteroventral periventricular nucleus (AVPV), which is thought to occur through apoptosis, confirmed that TRAF2-inhibiting protein could downregulate the TNF-α-TNF receptor 2-NF-κB-Bcl-2 pathway to inhibit cell survival in the male AVPV. 51 However, there is no consensus regarding the specific effects of TRAF2 on NF-κB and c-Jun activation. Related research has indicated that TRAF2 could promote the activation of both NF-κB and c-Jun in HEK293 cells. 52 However, other studies asserted that TRAF2 is an activator of NF-κB but inhibits c-Jun in MEFs subjected to TNF-α stimulation. 15, 20 In the present study, we demonstrated that TRAF2 Ser 55 phosphorylation could promote NF-κB activation but suppress c-Jun activation in Caco-2 cells subjected to H/R (Figure 7) . Therefore, our results verified that TRAF2 Ser 55 phosphorylation mediated suppression of H/R-induced apoptosis in Caco-2 cells may be related to promoting the activation of NF-κB and inhibiting the activation of c-Jun.
In conclusion, the present study showed that the PKCζ/ TRAF2 signaling pathway has an essential protective role in response to intestinal I/R injury. Upon intestinal I/R insult, PKCζ transfers to the cell membrane and recruits and phosphorylates TRAF2 at Ser 55 , but not at Ser 11 . Subsequently, TRAF2 Ser 55 phosphorylation activates NF-κB but inhibits c-Jun to attenuate cell apoptosis, leading to protection against the injury induced by intestinal I/R. Therefore, we believe that the PKCζ/TRAF2 signaling pathway represents a promising therapeutic target for intestinal I/R injury and related clinical diseases.
Materials and Methods
Murine model of intestinal I/R and treatment. Male C57BL/6 mice (aged 8 weeks) weighing 20 ± 2 g were obtained from the Animal Center of Dalian Medical University (Dalian, China). The mice were provided suitable food and water and were housed in an environment with controlled humidity, temperature, and light (12 h light/dark). The intestinal I/R model was generated as previously described. 21, 24 In brief, the mice were administered anesthesia via intraperitoneal injection of pentobarbital (40 mg/kg body weight) before midline laparotomy. Next, an atraumatic clip was used to occlude the superior mesenteric artery for 45 min, and then 90, 120, or 240 min of reperfusion was performed. Normal saline and PC (0.3 mM, Aladdin, Shanghai, China) were infused intraduodenally at 0.2 ml/h for 4 h prior to surgery. 23 Normal saline and ATM (60 mg/kg/day, Sigma-Aldrich, St. Louis, MO, USA) were injected intraperitoneally for 7 consecutive days prior to surgery. 22 The animal experiments were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals. All animal procedures were approved by the Institutional Ethics Committee of Dalian Medical University (Dalian, China).
Cell culture and H/R model. Caco-2 cells were cultured in a humidified incubator maintained at 37°C and 5% CO 2 in Dulbecco's modified Eagle's medium supplemented with 1% non-essential amino acids, 10% fetal bovine serum, and 1% glutamide (Gibco, Carlsbad, CA, USA). To generate the in vitro I/R model, cells were incubated for 12 h in a microaerophilic system (Thermo, Marietta, GA, USA) containing 5% CO 2 and 1% O 2 balanced with 94% N 2 gas. Then, the cells were cultured for 6 h under normoxic conditions to allow reoxygenation.
Transient transfection of siRNA. Caco-2 cells were transfected with a PKCζ siRNA (si-PKCζ) or a negative control siRNA (both obtained from GenePharma, Shanghai, China) using Lipofectamine 3000 (Invitrogen, Shanghai, China). The si-PKCζ had the following sequences: forward (F) 5′-GCAAACUGCUG GUCCAUAATT-3′ and reverse (R) 5′-UUAUGGACCAGCAGUUUGCTT-3′. The negative control siRNA had the following sequences: forward (F) 5'-ACGUGACAC GUUCGGAGAATT-3' and reverse (R) 5'-UUCUCCGAACGUGUCACGUTT-3'. All transfection processes were performed according to the manufacturer's instructions.
Plasmid construction and transient transfection. The TRAF2-WT plasmid, phospho-mutant TRAF2 plasmids (TRAF2-Ser55A and TRAF2-Ser55D) and the empty vector plasmid were synthesized by GenePharma. Caco-2 cells were transfected with 2 μg of the TRAF2-WT, TRAF2-Ser55A or TRAF2-Ser55D plasmid or the empty vector plasmid using Lipofectamine 3000 according to the manufacturer's instructions.
Western blotting analysis. Membranous or total proteins were extracted from intestinal tissue and Caco-2 cells using a commercial protein isolation kit (KeyGEN Biotech, Nanjing, China). Equal amounts of protein were analyzed using 10-15% SDS-PAGE (Bio-Rad, Hercules, CA, USA) and then were transferred to PVDF membranes (Millipore, Bedford, MA, USA). The membranes were incubated overnight at 4°C with the following corresponding primary antibodies: PKCζ, phospho-PKCζ (Thr   410   ) , and TRAF2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); phospho-TRAF2-Ser11 (Cell Signaling Technologies, CST, MA, USA); PKCλ (R&D Systems, MN, USA); cleaved caspase-3, Bcl-2, Na, K-ATPase, and Jun (Proteintech, Wuhan, China); phospho-Jun (Thr  91 +Thr   93 ) (BIOS, Beijing, China); β-actin (ZSGB-BIO, Beijing, China); and a phospho-TRAF2-Ser55 antibody that was custom made by GL Biochem (Shanghai, China). Then, the cells were incubated with homologous secondary antibodies for 2 h at 37°C. The bands were exposed using enhanced chemiluminescence-plus reagents (Beyotime Institute of Biotechnology). The images were documented using a BioSpectrum-410 multispectral imaging system, and the signals were analyzed using a Gel-Pro Analyzer (Version 5.0; Media Cybernetics, Rockville, MD, USA).
Immunofluorescence. Caco-2 cells were fixed using 4% paraformaldehyde for 30 min, washed three times with PBS, permeabilized with 0.2% Triton X-100 for 10 min, and then blocked with 2% bovine serum albumin in PBS at 37°C for 30 min. The specimen slides were incubated with the primary anti-PKCζ or anti-TRAF2 antibody at 4°C overnight, subsequently washed three times with PBS, and then incubated with FITC-(ZSGB-BIO) and Alexa Fluor 594-conjugated secondary antibodies (Proteintech) at 37°C for 1 h. After additional washes with PBS, the specimen slides were counterstained with the nuclear stain 4,6-diamidino-2-phenylindole (DAPI; Beyotime, Shanghai, China) at room temperature for 10 min. An 80i Nikon microscope (Tokyo, Japan) was used to examine the immunofluorescent images.
Co-immunoprecipitation. Membranes were extracted from the Caco-2 cells as described above. An equal amount of anti-PKCζ antibody was added to 500 μg of protein and gently shaken at 4°C overnight. Immunocomplexes were acquired by adding 40 μl of protein A+G agarose beads (Beyotime Institute of Biotechnology, Shanghai, China); then, the mixtures were gently shaken at 4°C for 4 h. The mixture was centrifuged at 1000 × g for 5 min at 4°C, and then the supernatant was discarded. The sediment was washed five times using ice-cold PBS. To separate the immunocomplexes from the beads, the immunocomplexes were boiled in sodium dodecyl sulfate sample buffer for 5 min. Then, the specimens were examined via western blotting with anti-PKCζ and anti-TRAF2 antibodies according to the manufacturer's instructions.
Histological and TUNEL staining. For the histological and TUNEL analyses, intestinal tissue was fixed in 4% formalin and then paraffin-embedded. Sections 4 μm in thickness were stained using hematoxylin and eosin. The histopathological scores of the intestinal tissues were determined according to the Targeting TRAF2 regulates gut ischemia-reperfusion W Zhou et al method of Chiu. 53 TUNEL staining was performed using an apoptosis detection kit (Roche, Branchburg, NJ, USA) according to the manufacturer's instructions.
Luciferase gene reporter assays. Caco-2 cells were cotransfected with NF-κB firefly luciferase reporter plasmid (GenePharma, Shanghai, China) and TRAF2-WT, TRAF2-Ser55A, TRAF2-Ser55D or an empty vector plasmid (2 μg/well) using Lipofectamine 3000. Reporter assays were performed 36 h after transfection. Luciferase activity was tested with a Double-Luciferase Reporter Assay Kit (TransGen Biotech, Beijing, China) using the Dual-Light Chemiluminescent Reporter Gene Assay System (Berthold, Germany) and was normalized to Renilla luciferase activity.
Real-time PCR. Total RNA was extracted from Caco-2 cells using TRIzol (Takara, Dalian, China). cDNA was synthesized using the TransScript All-in-One First-Strand cDNA Synthesis SuperMix for qPCR Kit (TransGen Biotech), and target cDNA was amplified with the corresponding primers (Invitrogen). The primer sequences were as follows: cIAP1, forward (F) 5-GCCTGATGCTGGATAACTGG-3 and reverse (R) 5′-GGCGACAGAAAAGTCAATGG-3′; IP-10, forward (F) 5′-CTAC TGAGGTGCTATGTTCTTAGTG-3′ and reverse (R) 5′-GTACCCTTGGAAGATGG GAAAG-3′; β-actin, forward (F) 5′-TCCACGAAACTACCTTCAAC-3′ and reverse (R) 5′-TTTAGGATGGCAAGGGAC-3′. The resulting cDNA was then subjected to quantitative real-time PCR using a TransStart Top Green qPCR SuperMix kit (TransGen Biotech). A 7500 Fast Real-time PCR System (Applied Biosystems) was used to analyze the specimens.
Cell viability assay. The tetrazolium salt Cell Counting Kit-8 (Dojindo Molecular Technologies, Inc., Tokyo, Japan) was used to determine cell viability according to the manufacturer's protocol.
Statistical analysis.
Values are presented as the means ± S.D. Comparisons between two groups were performed using a two-tailed Student's t-test. One-way analysis of variance and the Student-Newman-Keuls test were used to compare the means among multiple groups. All data analyses were performed with GraphPad Prism 5.0 (GraphPad Prism Software, La Jolla, CA, USA). Po0.05 was considered significant.
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